Month: March 2013

$OMER update

Althought this stock has fallen recently, I still contend it is a undervalued biotech stock. This stock fluctuates with the news of its drug trials. Most recently, its leading drug candidate OMS302 has had a successful phase III trial and no safety concerns were identified. If this drug is approved, sales could reach $600 million …

$OMER update Read More »

$MO update

Altria recently declared a regular quarterly divident of $0.44 per share, payable on 4/10/13 (Ex date is 03/13/13). As always, MO is susceptible to federal, state, and USDA regulation, and litigation but I am confident in its 2013 guidance. They have shown success in responding to consumer preferences and developing new products and markets.